Sequent Scientific's Q2 FY 2025-26 Quarterly Results

Result Summary

• Sequent Scientific Ltd reported a 4.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 14.2%.
• Its expenses for the quarter were down by 5.1% QoQ and up 10.1% YoY.
• The net profit increased 11.6% QoQ and increased 209.1% YoY.
• The earnings per share (EPS) of Sequent Scientific Ltd stood at 0.58 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sequent Scientific Ltd is a leading player in the pharmaceutical industry, primarily engaged in the development and manufacturing of veterinary pharmaceutical products. The company operates in the niche segment of animal healthcare, providing a range of products including active pharmaceutical ingredients (APIs) and formulations. Sequent Scientific has established a strong presence in the global market, with a focus on innovation and quality. Recent developments in the company have included strategic expansions and partnerships aimed at enhancing their product offerings and market reach. Specific recent developments or strategic changes within the company are not provided in the available data.

Revenue

During the second quarter of fiscal year 2026 (Q2FY26), Sequent Scientific Ltd reported a total income of ₹426.14 crores. This represents a decrease of 4.3% compared to the previous quarter (Q1FY26), where the total income was ₹445.29 crores. However, on a year-over-year basis, total income saw an increase of 14.2% from ₹373.16 crores recorded in the second quarter of fiscal year 2025 (Q2FY25). This year-over-year growth indicates an upward trend in revenue generation over the past year, despite the quarterly decline.

Profitability

Sequent Scientific Ltd's profitability in Q2FY26 showed significant improvements compared to both the previous quarter and the same quarter last year. The company reported a profit before tax of ₹27.16 crores, marking a 6.4% increase from ₹25.52 crores in Q1FY26. On a year-over-year basis, there was a remarkable increase of 243.8% from ₹7.90 crores in Q2FY25. The profit after tax for Q2FY26 was ₹19.60 crores, which is an 11.6% increase from the previous quarter and a substantial 209.1% increase from the same quarter last year. Earnings per share also improved, rising from ₹0.56 in Q1FY26 to ₹0.58 in Q2FY26, and showing a significant year-over-year growth of 480% from ₹0.10 in Q2FY25.

Operating Metrics

The total expenses for Sequent Scientific Ltd in Q2FY26 amounted to ₹397.28 crores, which is a 5.1% decrease from the previous quarter's expenses of ₹418.52 crores. Year-over-year, total expenses increased by 10.1% from ₹360.94 crores in Q2FY25, indicating a rise in operating costs over the past year. The tax expense for the company in Q2FY26 was ₹7.56 crores, slightly down by 4.9% from ₹7.95 crores in Q1FY26. However, compared to the same quarter last year, tax expenses rose by 384.6% from ₹1.56 crores in Q2FY25. These financial metrics reflect the company's operational efficiency and cost management strategies during this period.